title: [Economic evaluation of various hepatitis B vaccination strategies in children and adolescents].
abstract: OBJECTIVE
  In this cost-effectiveness study 4 different vaccination strategies against hepatitis B in children and adolescents are evaluated and compared with the situation without immunization.
  
  
  RESULTS
  Projections are made for the population of the today's adolescents underage 15 and the newborns of the next 30 years. The number of avoided hepatitis B virus (HBV) infections and the cases of disease as well as the costs associated with treatment and vaccination are determined. The course of incidence of the hepatitis B virus is observed for different age groups.
  
  
  RESULTS
  Compared to the situation without any vaccination against hepatitis B, a decrease of the remaining infections of at least 18,900 up to 46,600 could be expected during the next 30 years. The treatment costs for the remaining cases of disease could be reduced by 0.4 up to 1.6 billions DM. The remaining expenditures for treatment and vaccination would be limited to 2.3 up to 3.4 billions DM. The net costs of a vaccination are determined as about 14,200 up to 63,000 DM per avoided case of infection. Considering the commonly accepted number of unreported cases of hepatitis B as to be the 5- to 10 fold of the known incidence, all of the 4 compared vaccination strategies will be cost-effective and associated with net savings of about 5,900 up to 36,400 DM per avoided case of hepatitis B virus infection during 30 years. The epidemiological situation will be positive influenced by such a mass vaccination. The minimization of incidence is shown for the different age groups.
  
  
  CONCLUSIONS
  Considering these economical arguments, first the vaccination of all adolescents between age 11 to 15 and second the vaccination of all children/adolescents between age 0 to 15 are the preferable strategies. The immunization of all children/adolescents between age 0 to 15 is the most effective strategy from an epidemiological point of view.
authors.affiliation: Zentrum für Pharmakoökonomie, Universität Mailand. merg.munich@t-online.de
authors.forename: T D
authors.initials: TD
authors.lastname: Szucs
authors.forename: A
authors.initials: A
authors.lastname: Smala
authors.forename: K
authors.initials: K
authors.lastname: Berger
authors.forename: A
authors.initials: A
authors.lastname: Windorfer
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D005260:Female; D005858:Germany / Q000453:epidemiology; D006509:Hepatitis B / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007223:Infant; D007231:Infant, Newborn; D008297:Male
chemical_list: D017325:Hepatitis B Vaccines